Please provide your email address to receive an email when new articles are posted on . In certain settings. Whether a patient has cancer or not, we are trained to reach into our toolbox for whatever ...
From September 1999 to April 2001, 57 patients underwent allogeneic BMT or PBSC transplantation in our transplant unit. Only patients with hematological malignancies and conventional conditioning were ...
Despite showing preclinical promise, granulocyte colony-stimulating factor (G-CSF) fails to improve clinical outcomes in acute ischemic stroke patients, according to results published online August 20 ...
The myeloablative therapy before SCT is associated with prolonged pancytopenia, which can result in serious morbidity and life-threatening complications due to infections and bleeding. 9 ...
Clinical studies examining the use of G-CSF in critically ill patients without hematologic disease and immunosuppression included mostly patients with severe sepsis and septic shock. These studies ...
Granulocyte-colony stimulating factors (G-CSFs) reduce the risk of febrile neutropenia in patients with cancer. This study evaluates the clinical and nonclinical value associated with G-CSFs.
Despite a meaningful survival, neutropenia is independently associated with poor outcomes among critically ill patients with cancer, according to a new study. However, neutropenia was no longer ...
The persuasive Global G-CSF/PEG-G-CSF Market report suggests that the key market players are making moves like product launches, joint ventures, developments, mergers and acquisitions which has ...
New York, March 03, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback